When less is more: maintenance therapy in colorectal cancer
Mené sur 558 patients atteints d'un cancer colorectal métastatique, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement d'entretien combinant capécitabine et bévacizumab (durée médiane de suivi : 48 mois)
The aim of palliative therapy in oncology is to prolong life and maintain quality of life for patients, with the least therapy necessary to control disease. The improvement in overall survival seen in metastatic colorectal cancer over the past decade is intrinsically associated with the increased number of active drugs in the management of disease, and a better understanding of how best to use these drugs. The availability of improved supportive care, less toxic regimens, and targeted drugs have led to a shift in the treatment paradigm.
The Lancet , commentaire, 2014